Xue Ling

Dr. Xue Ling


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2014 in Molecules
Verified
Journal Article
Open access
PDF file
HCHong Chen
Hong Chen
XLXue Ling
Xue Ling
FXFang Xu
Fang Xu
BXBingbing Xu
Bingbing Xu
XHXuelan He
Xuelan He
MYMu Yuan
Mu Yuan
A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines (PC-3, LNCaP, and DU145) were evaluated by a CCK-8 assay. Compounds 9 and 15 exhibited strong cytotoxic activities against LNCaP cells (IC50 < 5 μM), and compound 8 (IC50 = 8.25 μM) possessed the most potent activity against DU145 cells. However, these compounds also exhibited cytotoxicity towards human epithelial prostate normal cells RWPE-1. The structure–activity relationship (SAR) of these arylpiperazine derivatives was also discussed based on the obtained experimental data.

20 August 2014 in Molecules
Verified
Journal Article
Open access
PDF file
FXFang Xu
Fang Xu
HCHong Chen
Hong Chen
XHXuelan He
Xuelan He
JXJingyi Xu
Jingyi Xu
BXBingbing Xu
Bingbing Xu
MYMu Yuan
Mu Yuan
α1-Adrenoceptors (ARs; 1A, 1B, and 1D) have been determined to perform different prominent functions in the physiological responses of the sympathetic nervous system. A high-throughput screening assay (HTS) was set up to detect α1-AR subtype-selective agonists by a dual-luciferase reporter assay in HEK293 cells. Using the HTS assay, two novel compounds, CHE3 and CHK3, were discovered as α1-ARs agonists in α1-ARs expressed in HEK293 cells. These compounds also showed moderate/weak anti-proliferative activities against tested cancer cell lines. The HTS assay proposed in this study represents a potential method for discovering more α1-AR subtype-selective ligands.

24 January 2026 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
YCYi Chen
Yi Chen
ZLZhaoyu Liu
Zhaoyu Liu
ZMZesen Mai
Zesen Mai
YZYongbing Zhou
Yongbing Zhou
HWHuiwen Wen
Huiwen Wen
XLXue Ling
Xue Ling